A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Vedran Radojcic, M.D.
Syndax Pharmaceuticals
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Alabama at Birmingham
Birmingham, Alabama, United States
- City of Hope
Duarte, California, United States
- University of Miami Miller School of Medicine
Miami, Florida, United States
- Indiana University Health Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States
- Massachusetts General Hospital
Boston, Massachusetts, United States
- Karmanos Cancer Institute
Detroit, Michigan, United States
- University of Minnesota Medical Center
Minneapolis, Minnesota, United States
- Washington University School of Medicine
St Louis, Missouri, United States
- Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
- University of Utah Health Huntsman Cancer Institute
Salt Lake City, Utah, United States
- Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 1 Nov 2018
- Primary completion
- 12 Aug 2022
- Completion
- 18 Oct 2024
- Last update posted
- 15 Sept 2025
- Registered enrollment
- 41
- Registry id
- NCT03604692
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.